The 37/405 (9.1%) participants who did not complete the final study visit had similar characteristics (age, sex, HIV status, TB microbiology, SES) to those who completed the study, but lower average CD4 counts at TB-treatment completion (113 cells/μL (IQR: 62–197) vs 244 cells/μL (IQR: 137–398), p=0.007)(online supplemental S3 appendix). The gene discussed is CD4; the disease is tuberculosis.